Oral Delivery of Novel Recombinant <i>Lactobacillus</i> Elicit High Protection against <i>Staphylococcus aureus</i> Pulmonary and Skin Infections
<i>Staphylococcus aureus</i> is a leading cause of nosocomial and community-associated infection worldwide; however, there is no licensed vaccine available. <i>S. aureus</i> initiates infection via the mucosa; therefore, a mucosal vaccine is likely to be a promising approach...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/9/984 |